AAD 2026: Owning Psoriatic Disease, With Lindsay Ackerman, MD

From the first United States Food and Drug Administration (US FDA)-approved oral IL-23 receptor antagonist to new data suggesting that biologics may delay the onset of psoriatic arthritis (PsA), the 

2026 American Academy of Dermatology (AAD) Annual Meeting

During the meeting held in Denver, Colorado, from March 27-31, 

spoke with Lindsay Ackerman, MD, FAAD, who came away from Denver more convinced than ever that dermatologists should be taking ownership of the full psoriatic disease burden in their patients.

Ackerman serves as Chief of Dermatology at Banner University Medical Center, Clinical Associate Professor at the University of Arizona, Medical Director of the US Dermatology Partners Clinical Research Institute, and President of Medical Dermatology Specialists in Phoenix. The conversation ranged across the evolving oral treatment landscape, new data on PsA prevention, the late-breaking TOGETHER-PsA incretin combination results, and what Ackerman described as an exciting but still-early reckoning with how obesity management intersects with chronic inflammatory disease. 

Roughly 30% or more of psoriasis patients are likely to develop PsA at some point, and with emerging data showing that both risankizumab and guselkumab are demonstrating delay-to-onset and risk-reduction signals for PsA, Ackerman argued that dermatologists who are already managing these patients' skin disease have both the opportunity and the responsibility to engage with the joint disease — not to displace rheumatology colleagues, but to recognize that the majority of this patient population will be seen first and most frequently in the derm chair.

On the IL-23 front, the headline development for Ackerman was the FDA approval of icotrokinra (ICOTYDE) — the first oral IL-23 receptor antagonist, approved for adults and pediatric patients 12 and older weighing at least 40 kg, dosed once daily — which she characterized as a genuinely new lane for a psoriasis oral market that has historically underperformed relative to biologics. She highlighted the head-to-head data versus deucravacitinib as an important differentiator, and noted that the dosing logistics are manageable: once-daily on waking, with 30 minutes before food, compatible with morning coffee.

 Looking further ahead, she noted that Apogee Therapeutics and Takeda are both advancing oral agents targeting IL-23 or its receptor in phase 2a and phase 3 trials respectively — a pipeline that signals the field is serious about giving patients who prefer oral therapy a genuinely competitive option. The TOGETHER-PsA data showing superior ACR50 plus ≥10% weight loss outcomes with ixekizumab plus tirzepatide versus ixekizumab alone also caught Ackerman's attention — not as a settled paradigm, but as the first controlled signal that pharmacologic co-management of obesity in psoriatic disease may amplify inflammatory disease outcomes in ways anecdotal reports and meta-analyses had only suggested. The 52-week data and companion TOGETHER-PsO results are still to come, and Ackerman was careful to frame the obesity-inflammation intersection as a frontier the field is only beginning to quantify — but one she finds genuinely compelling.

“Medical dermatology has been evolving for the past 2 decades in ways that have escalated and escalated and escalated what our treatment options look like. We're now looking at patients with a different set of eyes, a different lens, into what we can therapeutically achieve. And to me, it's just a brilliant moment,” Ackerman said.

Relevant disclosures for Ackerman include AbbVie, Alumis, Amgen, Arcutis, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, L'Oréal, Novartis, Sun Pharmaceutical, and UCB.

Johnson & Johnson. FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide. Press release. March 18, 2026. 

https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide

Merola JF, et al. Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial. 

Eli Lilly and Company. Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity. Press release. March 28, 2026. 

https://investor.lilly.com/news-releases/news-release-details/phase-3b-data-presented-aad-annual-meeting-show-lillys-taltz

Videos

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Experts examine CSU endotypes and their implications for treatment selection and preview the emerging therapeutic pipeline including barzolvolimab and novel mast cell–depleting strategies.

Managing Established Patients: Switching, Adherence, Spontaneous Remission, and Treatment Duration 

Chronic spontaneous urticaria is increasingly understood as a heterogeneous condition driven by distinct immunological endotypes rather than a single unified pathophysiological mechanism. At least 2 major subtypes have been described: type I, characterized by IgE-mediated mast cell activation through the high-affinity IgE receptor (FcεRI), and type IIb, in which IgG autoantibodies directly activate mast cells via FcεRI or other receptors in an IgE-independent manner. This mechanistic complexity helps explain the variable response to omalizumab and informs the rationale for agents with broader or alternative mechanisms. Remibrutinib acts at the BTK convergence point downstream of both IgE-mediated and non-IgE-mediated mast cell activation pathways, giving it theoretical breadth across endotypes; dupilumab's inhibition of IL-4Rα targets the type 2 inflammatory milieu at a different level, potentially relevant in patients whose disease is amplified by type 2 cytokine activity. As the field accumulates head-to-head data and real-world experience with all 3 agents, endotype-informed treatment sequencing may become increasingly feasible.

The CSU pipeline is active. Barzolvolimab, an anti-KIT monoclonal antibody under investigation by Celldex, targets the mast cell directly via the stem cell factor receptor — an approach with theoretical advantages across endotypes, since eliminating the effector cell renders the upstream activating mechanism clinically irrelevant. Data presented at a recent major allergy meeting included safety and long-term efficacy results for barzolvolimab, as well as new remibrutinib data in chronic inducible urticaria and a preliminary signal for high-dose remibrutinib (75 mg twice daily) in the prevention of food-induced anaphylaxis. If mast cell–depleting strategies achieve approval, they may fundamentally alter the treatment algorithm by addressing the shared final effector pathway irrespective of immunological subtype. Remibrutinib's emerging signals in conditions beyond CSU further suggest that BTK inhibition may have broader utility across mast cell–driven disease.

In this final video segment, Nicole Chase, MD, and Jason Hawkes, MD, address the persistent problem of systemic corticosteroid use in CSU, a pattern both characterize as clinically concerning despite the availability of effective, targeted, steroid-sparing agents. While short-term corticosteroid bridges have a defined role in acute severe exacerbations, repeated courses and chronic low-dose oral prednisone expose patients to well-characterized toxicities, such as metabolic dysfunction, adrenal suppression, osteoporosis, and infection risk, that are disproportionate to the disease burden of CSU, which carries no risk of end-organ damage or mortality. Hawkes draws a pointed risk-framing comparison: clinicians who express concern about remibrutinib's approximately 4% rate of mild bruising and petechiae should weigh that against the hemorrhagic, metabolic, and immunosuppressive risks of even short-term corticosteroid exposure. The availability of fast-acting targeted therapies — particularly remibrutinib — substantially reduces the clinical scenarios in which corticosteroids are genuinely the best available option, and clinicians should systematically revisit steroid-dependent patients to initiate discussions about transition to guideline-concordant care.

Disease Mechanisms, Emerging Therapies, and Reducing Corticosteroid Reliance in CSU 

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Lebrikizumab-lbkz (EBGYLSS) treatment may lead to up to 4 years of durable disease control for individuals with 

These findings on lebrikizumab suggest the interleukin-13 (IL-13) inhibitor may offer sustained disease control for patients with atopic dermatitis, with durability of both skin clearance and itch reduction extending up to 4 years. The findings were presented in a poster session at the 

"There is still an unmet need for people with moderate-to-severe atopic dermatitis who frequently experience unpredictable flares and are in need of treatment options that go beyond just symptomatic relief and address the underlying inflammation driving skin symptoms and persistent itch," Emma Guttman-Yassky, MD, PhD, the Waldman Professor and Health System Chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, said in a statement.

Lebrikizumab was designed to selectively inhibit IL-13, a central cytokine in the type 2 inflammatory pathway involved in atopic dermatitis’s pathophysiology. Through the targeting IL-13 signaling, this medication could help to disrupt key drivers of the condition, including epidermal barrier dysfunction, skin thickening, chronic itch, and patients’ susceptibility to infection.

Lebrikizumab’s efficacuy and safety in patients with atopic dermatitis was evaluated in the ADlong trial (NCT05916365), with a 250 mg dose having been administered every 4 weeks over a 108-week treatment period. The investigators’ study population included patients aged 12 - 17 years (weighing at least 40 kg) who previously finished out the earlier pivotal and extension studies, including ADjoin, ADore, ADhere, and ADvocate 1 and 2.

In the current analysis, there were 174 individuals received open-label treatment with monthly lebrikizumab therapy, regardless of any previous dosing frequency. Overall, the study’s results suggest a substantial proportion of those on the drug maintained high levels of disease control over time. The team found the majority attained near-complete skin clearance, as measured by stringent endpoints such as EASI-90 and Investigator’s Global Assessment (IGA) scores of 0 or 1, alongside meaningful itch severity reductions based on the Pruritus Numeric Rating Scale (NRS).

Notably, the investigators found such outcomes largely were achieved with monotherapy, as 77% of those assessed did not require concomitant systemic or topical treatments. Approximately 80% of those assessed in the analysis maintained disease control without the use of topical corticosteroids, underscoring the potential of lebrikizumab as a standalone maintenance therapy.

Importantly, efficacy outcomes were sustained with a simplified dosing regimen. Specifically, the investigative team found 80% of subjects saw such clinical responses while on once-monthly injections of lebrikizumab. These data build on prior evidence supporting the durability of IL-13 inhibition and suggest that extended dosing intervals may be sufficient to maintain long-term disease control in many individuals.

Consistency was observed in the drug’s safety findings from the initial year of ADlong with the established profile of lebrikizumab, with a lack of newly-found safety signals observed. Most treatment-emergent adverse events were found to be mild to moderate in severity. They also did not result in treatment cessation. The most commonly reported events included conjunctivitis in 6.9% of patients and injection-site reactions in .6%.

"These four-year findings reinforce that [lebrikizumab] has the potential to deliver durable disease control, helping patients flare less with or without topicals,” Guttman-Yassky said in her statement.

The ADlong study was described by Lilly as remaining ongoing, with an additional year of follow-up slated for the drug’s evaluation.

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis. Eli Lilly. March 26, 2026. Accessed April 1, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-ebglyss-lebrikizumab-lbkz-delivered-four-years-durable

Weidinger S, et al. Efficacy and Safety of Lebrikizumab is Maintained up to 4 Years in Patients With Moderate-to-Severe Atopic Dermatitis: first year of ADlong Long-Term Extension Trial. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Articles

Lebrikizumab-lbkz, a selective IL-13 inhibitor, demonstrated durable control of moderate-to-severe atopic dermatitis through up to 4 years, with sustained skin clearance and pruritus improvement. In the ADlong open-label extension, patients (including adolescents ≥40 kg) received 250 mg every 4 weeks for 108 weeks after completing prior pivotal/extension programs. Most participants achieved stringent responses (EASI-90; IGA 0/1) and clinically meaningful Pruritus NRS reductions, frequently without concomitant topical or systemic therapy. Safety remained consistent without new signals.

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Lebrikizumab for Atopic Dermatitis Leads to 4 Years of Clearance, Itch Reduction

ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

For dermatologists and the dermatology community, the 

American Academy of Dermatology (AAD) Annual Meeting

 has earned the reputation as a platform the next wave of practice-changing advances in the field. The 2026 AAD annual meeting served as a prime example of why, with more than a dozen phase 2 or phase 3 trials headlining the conference—showcasing new data in psoriasis, atopic dermatitis, and more.

hosts Chris Bunick, MD, PhD, of Yale School of Medicine, and Lindsay Ackerman, MD, of US Dermatology Partners, break down a trio of late-breaking trials from the meeting and share their perspective on additional data of note across multiple disease states.

On March 28, 2026, Eli Lilly announced positive phase 3b results from the TOGETHER-PsA trial evaluating concomitant ixekizumab (Taltz) and tirzepatide (Zepbound) versus ixekizumab alone in adults with active psoriatic arthritis and obesity or overweight.

In the randomized, open-label trial of 271 participants, the combination arm met the primary endpoint, ACR50 response plus ≥10% weight reduction at 36 weeks, in 31.7% of patients versus 0.8% with ixekizumab monotherapy, with improvements in disease activity, fatigue, physical function, and cardiometabolic markers also favoring the combination. Adverse events in the combination arm were generally mild to moderate and consistent with the established profiles of each agent, with nausea, diarrhea, and constipation among the most common.

Eli Lilly indicated detailed findings will be discussed with regulators, though no submission timeline was disclosed.

On March 23, 2026, Apogee Therapeutics announced positive 52-week maintenance data from Part A of the phase 2 APEX trial evaluating zumilokibart, an extended half-life anti-IL-13 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis.

Based on the trial's maintenance phase, EASI-75 response was maintained at week 52 in 75% and 85% of week 16 responders receiving every-3-month and every-6-month dosing, respectively, with deepening of response observed across lesional and itch endpoints in the full treated population through 52 weeks. Zumilokibart's extended half-life design supports dosing as infrequently as twice yearly, compared with up to 26 annual injections for currently available therapies, with a safety profile consistent with other agents in the IL-13 class.

Part B 16-week induction data are expected in the second quarter of 2026, with phase 3 initiation in moderate-to-severe atopic dermatitis planned for the second half of 2026.

On March 28, 2026, Takeda announced positive phase 3 results from the Latitude PsO 3001 and 3002 trials evaluating zasocitinib, a once-daily oral selective TYK2 inhibitor, in adults with moderate-to-severe plaque psoriasis.

In the randomized, double-blind, placebo- and active comparator-controlled trials, 71.4% and 69.2% of zasocitinib-treated patients achieved sPGA 0/1 at week 16 versus 10.7% and 12.6% with placebo and 32.1% and 29.7% with apremilast (

<.001), with PASI 75 responses observed as early as week 4 and more than 90% of week 40 responders maintaining response through week 60. The safety profile was consistent with phase 2b data, with upper respiratory tract infection, nasopharyngitis, and acne among the most common adverse events and no new safety signals were identified.

Takeda plans to submit a New Drug Application to the FDA starting in fiscal year 2026.


Relevant disclosures for Bunick include AbbVie, South Beach Symposium, Almirall, Apogee Therapeutics, Arcutis Biotherapeutics, Daiichi Sankyo, Eli Lilly, LEO Pharma, US, Novan, Novartis, Ortho Dermatologics, Palvella Therapeutics, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Timber Pharmaceuticals, and UCB. Relevant disclosures for Ackerman include AbbVie, Alumis, Amgen, Arcutis, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, L'Oréal, Novartis, Sun Pharmaceutical, and UCB.

Eli Lilly and Company. Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity | Eli Lilly and Company. Eli Lilly and Company. Published March 28, 2025. Accessed April 2, 2026. 

Apogee Therapeutics. Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis | Apogee Therapeutics, Inc. Apogee Therapeutics, Inc. Published March 23, 2026. Accessed April 2, 2026. 

https://investors.apogeetherapeutics.com/news-releases/news-release-details/apogee-therapeutics-announces-positive-phase-2-part-52-week-datq

Takeda. Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care. Takeda.com. Published March 28, 2026. Accessed April 2, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-phase3-clinical-trial-results/

Podcasts

Late-breaking AAD 2026 trials spotlight PsA weight-loss combo, twice-yearly IL-13 dosing for atopic dermatitis, and a rapid oral TYK2 pill for psoriasis.

ABCs in Dermatology

Welcome to ABC’s in Dermatology, HCPLive’s newest dermatology podcast, hosted by a pair of the field’s leading minds in Lindsay Ackerman, MD, and Chris Bunick, MD, PhD.

Created by the same team behind The Medical Sisterhood and Skin of Color Savvy, ABCs in Dermatology is a monthly podcast designed to deliver candid conversations, clinical insight, and forward-looking perspectives from the voices shaping dermatology today.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD

An oral selective JAK1 inhibitor has demonstrated sustained and deepening clinical response through 54 weeks in moderate-to-severe 

, with up to 29% of patients achieving complete abscess and inflammatory nodule clearance — adding a mechanistically distinct option to a treatment landscape that has expanded rapidly but remained anchored to injectable biologics.

To discuss the findings, we spoke with Martina L. Porter, MD, of Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, presenting author of the 54-week STOP-HS data at the 

 held in Denver, Colorado, from March 27-31. STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) are identically designed global phase 3 trials enrolling 1,227 adults total (STOP-HS1, n = 608; STOP-HS2, n = 619) with moderate-to-severe HS, randomized 1:1:1 to povorcitinib 75 mg once daily, 45 mg once daily, or placebo for a 12-week placebo-controlled period, followed by a 42-week blinded extension through week 54. Patients were required to have AN count ≥5 in ≥2 anatomic areas, Hurley stage II or III, disease duration ≥3 months, and prior systemic therapy — with 37.2% having previously received a biologic. Mean disease duration was 10.3 years (SD 9.4), mean AN count 12.0 (SD 8.8), and 75.5% had at least 1 draining tunnel at baseline.

At the primary endpoint of HiSCR50 at week 12, both doses were statistically significant versus placebo in both studies — 40.2% (45 mg) and 40.6% (75 mg) versus 29.7% placebo in STOP-HS1 (

 <.025), and 42.3% for both doses versus 28.6% placebo in STOP-HS2 (

 <.01) — with continuous improvement through week 54. By observed-cases analysis at week 54, HiSCR50 reached 60.2%–61.9% (STOP-HS1) and 57.3%–67.5% (STOP-HS2) in patients on continuous povorcitinib, with placebo crossover patients achieving comparable rates after switching at week 12. High-threshold responses deepened comparably, with up to 29.0% of patients achieving HiSCR100 at week 54. Full clearance of all inflammatory lesions (ANdT = 0) was achieved in 16.1%–20.2% of patients across both studies. Clinically meaningful improvements were observed across patient-reported outcome measures at week 54: ≥3-point decreases in skin pain NRS in 40.5%–58.0% of eligible patients, ≥4-point improvements in FATIGUE (FACIT-F) in 40.5%–49.0%, ≥4-point decreases in DLQI in 59.4%–64.7%, and ≥21-point decreases in HiSQoL total score in 33.7%–40.2%. 

Safety through week 54 was consistent with the class profile — the most common TEAEs were acne (16.4%–21.1%), nasopharyngitis (9.4%–13.6%), and upper respiratory tract infection (9.1%–12.2%). Serious TEAEs occurred in 3.7%–6.4% of patients across arms, with no malignancies excluding NMSC reported and MACE occurring in only 1 patient (0.3%) in STOP-HS2. Porter contextualized povorcitinib's JAK1 mechanism as genuinely complementary to existing options: while TNF-α and IL-17 inhibitors — including secukinumab, bimekizumab, and the phase 3-complete agents izokibep and imsidolimab — share overlapping proximity in the inflammatory signaling cascade, JAK-STAT pathway inhibition operates through a distinct mechanism that may benefit patients who have already failed biologic therapy, and Porter suggested it could potentially be considered first line pending the FDA approval pathway.

“For some patients who have already taken biologics and had very minimal response, this could be very promising for them especially. But I've also seen in clinical practice that it has a variety effects of on different types of HS patients, and so I also think it could be considered first line in the future as well, depending on how It's [potentially] approved through the FDA,” Porter said.

Relevant disclosures for Porter include Abbvie, Bristol Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, UCB, Trifecta Clinical, Incyte, and Anaptys Bio.

Porter ML, Martorell A, Sayed CJ, et al. Povorcitinib in patients with moderate to severe hidradenitis suppurativa: 54-week efficacy and safety results from the STOP-HS1 & STOP-HS2 phase 3 studies. Presented at: American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Presentation 80034.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Rethinking When and How to Treat IgA Nephropathy, With Sayna Norouzi, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

Tips on Strategies for Psoriasis in Skin of Color, With Eingun James Song, MD

Joseph Rossano, MD, MS, is the co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten’s comparative superiority in reducing left ventricular outflow.

SCOUT-HCM: Mavacamten Outperforms Placebo in Adolescents With HCM, With Joseph Rossano, MD, MS

Andres Gelrud, MD, is a gastroenterologist at Baptist Health Miami Cancer Institute, part of Baptist Health South Florida

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face. 

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Beyond Chronic Pancreatitis, Rethinking Who Gets EPI and How We Treat It, With Andres Gelrud, MD

Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London.

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.


Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Late-Onset Depression Linked to Increased Dementia Risk, With Lingfeng Xue, PhD

Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Next Steps for Upadacitinib in Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The Agency approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight. It can be taken any time of the day without restrictions on food and water intake.

FDA News

FDA Approves Orforglipron (Foundayo) As First Daily GLP-1 Pill Without Food, Water Restrictions

Christopher Chan, MD, is director of the division of nephrology, professor of medicine, and R Fraser Elliott Chair in Nephrology at Toronto General Hospital, University Health Network.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

Latest News

AAD 2026: Owning Psoriatic Disease, With Lindsay Ackerman, MD

Disease Mechanisms, Emerging Therapies, and Reducing Corticosteroid Reliance in CSU

Lebrikizumab for Atopic Dermatitis Leads to 4 Years of Clearance, Itch Reduction

ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

Povorcitinib Delivers Deepening Responses Through 54 Weeks in Moderate-to-Severe HS, With Martina Porter, MD